FacebookTwitterGoogle Bookmarks

6 Vaccins candidats pour le COVID-19: où on en est?

Le développement d'un vaccin efficace nécessite en temps normal 10 à 15 ans de recherche. Mais face au caractère pandémique de cette maladie, un effort international a été déployé pour trouver un vaccin en 18 mois.

En Avril 2020, l'OMS a recencé une soixantaine de vaccins potentiels pour lutter contre le COVID-19. Ce document considère seulement deux vaccins en phase clinique à savoir l'américain "mRNA-1273" et le chinois "Adenovirus Type 5 Vector". Cependant, une analyse des données du registre américain Clinicaltrials révèle qu'au moins six de ces vaccins sont déjà en phase 1. Ces derniers sont décrits dans le tableau suivant:

NCT Number

Title

Conditions

Interventions

Sponsor/Collaborators

Age

Phase

Start Date

Completion Date

NCT04299724

Safety and Immunity of Covid-19 aAPC Vaccine

Treat and Prevent Covid-19 Infection

Biological: Pathogen-specific aAPC

Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital

6 Months to 80 Years   (Child, Adult, Older Adult)

I

February 15, 2020

December 31, 2024

NCT04334980

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

COVID-19

Biological: bacTRL-Spike

Symvivo Corporation

19 Years to 55 Years   (Adult)

I

April 30, 2020

December 31, 2021

NCT04324606

A Study of a Candidate COVID-19 Vaccine (COV001)

Coronavirus

Biological: ChAdOx1 nCoV-19|Biological: MenACWY Placebo

University of Oxford

18 Years to 55 Years   (Adult)

I/II

April 2020

May 2021

NCT04276896

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Pathogen Infection Covid-19 Infection

Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs

Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital

6 Months to 80 Years   (Child, Adult, Older Adult)

I/II

March 24, 2020

December 31, 2024

NCT04283461

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection

Corona Virus Infection|Immunisations

Biological: mRNA-1273

National Institute of Allergy and Infectious Diseases (NIAID)

18 Years to 55 Years   (Adult)

I

March 3, 2020

June 1, 2021

NCT04313127

A Phase I Clinical Trial in 18-60 Adults (APICTH)

COVID-19

Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital

18 Years to 60 Years   (Adult)

I

March 16, 2020

December 20, 2022

NCT04336410

Safety, Tolerability and Immunogenicity of INO-4800 in Healthy Volunteers

Coronavirus Infection

Drug: INO-4800|Device: CELLECTRA® 2000

Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI)

18 Years to 50 Years   (Adult)

I

April 2020

November 2020

Source : clinicaltrials.gov

Pour en savoir plus

DRAFT landscape of COVID-19 candidate vaccines – 4 April 2020

Calendrier

Juin 2024
Lun Mar Mer Jeu Ven Sam Dim
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Newsletter